Press Releases
-
Dec 18, 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the 37th Annual J.P. Morgan Healthcare Conference...
-
Dec 3, 2018
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the promotion of Amy Wireman to Group Vice President, Human Resources. Ms. Wireman's promotion to lead the Human Resources function...
-
Dec 3, 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in Citi's 13th Annual Biotech Conference on December 5 in New York City. To access the live webcast,...
-
Nov 12, 2018First-of-its-Kind Musical Featuring 25 High-School Students Affected by Bleeding Disorders Premieres in Broadway Theater
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the debut of the Broadway-style 'Hemophilia: The Musical,' a first-of-its-kind theatrical production featuring 25 students affected by a...
-
Nov 8, 2018- Credit Suisse 27th Annual Credit Suisse Healthcare Conference on November 13 in Scottsdale, AZ
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in two investor conferences this November. To access the events that are accessible by live webcasts,...
-
Nov 7, 2018Vosoritide for Achondroplasia: Demonstrates Continued Increased Growth through 42 months in Phase 2; Global Phase 3 Fully Enrolled
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) updated the investment community on the Company's research and development portfolio, which is focused on innovative therapies to treat rare and...
-
Nov 1, 2018Key Research & Development Pipeline Products and Data to be Presented, Including:
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host an R&D Day from 8:30am (ET) to 11:30am (ET) on Wednesday, November 7, 2018 in New York City. BioMarin management and external experts will...
-
Oct 25, 2018- First Nine Months of 2018 Total Revenues Grow 19% Year-over-year to $1.14 Billion
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 % Change 2018 2017 % Change Total...
-
Oct 16, 2018FDA Approval Triggers $15 Million Payment
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Company earned $15 million in milestone payments from Pfizer Inc. These milestone payments were triggered by the U.S. Food and...
-
Oct 11, 2018The young adults, each affected by a bleeding disorder, will perform in the Broadway-style musical upon completion of the 'Breaking Through!' Musical Theater Intensive workshop
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the twenty-five high school students from across the U.S. who will participate in 'Hemophilia: The Musical,' a first-of-its-kind...
-
Oct 11, 2018Company listed amongst top five biotech employers
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that Forbes' named the company to its list, Global 2000: World's Best Employers. It is ranked within the top 300 out of a total of 2000...
-
Oct 4, 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Sep 19, 2018Cantor Fitzgerald Global Healthcare Conference on October 1 in New York City
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in two investor conferences this October. To access the events that are accessible by live webcasts,...
-
Sep 5, 2018Updated results from Phase 1/2 program for tralesinidase alfa (formerly BMN 250)
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present 20 poster presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Symposium...
-
Aug 22, 2018- Citi's 13th Annual Biotech Conference on September 5-6 in Boston
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in three investor conferences this September. To access the events that are accessible by live...
-
Aug 2, 2018- Total Revenues of $372.8 million in the Quarter
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2018 2017 % Change 2018 2017 % Change Total Revenues $ 372.8
-
Jul 11, 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
-
Jul 9, 2018First-of-Its-Kind Musical to Help Empower the Bleeding Disorder Community to Find and Use their Voices through the Power of Music
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced an exclusive partnership with Believe Limited to produce the 'Breaking Through!' musical theater intensive. The first-of-its-kind...
-
Jun 28, 2018Five Students with Rare Genetic Diseases Receive a Total of $20,000 for Higher Education
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that it has awarded the first five recipients of the RARE Scholars program, an annual scholarship for students living with rare disease....
-
Jun 14, 2018
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company dosed the first participant in a global Phase 2 study for vosoritide, an analog of C-type Natriuretic Peptide (CNP), in...
-
Jun 7, 2018
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Company received $20 million in milestone payments from Pfizer Inc. These milestone payments were triggered by the U.S. Food...
-
May 24, 2018First Enzyme Therapy to Treat PKU
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that BioMarin received standard approval from the U.S. Food and Drug Administration (FDA) for Palynziq™ (pegvaliase-pqpz) Injection to...
-
May 22, 2018Eliminated Need for Prophylaxis and No Spontaneous Bleeds in Year 2
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec (formerly BMN 270), an...
-
May 17, 2018Platform Presentation to Highlight Data from Ongoing Phase 1/2 Study to Assess Long-Term Efficacy and Safety of Valoctocogene Roxaparvovec in Severe Hemophilia A
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the company will present data in one platform presentation and three poster presentations at the World Federation of Hemophilia...
-
May 15, 2018
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has dosed the first patient in a Phase 1/2 study (BMN 270-203) evaluating its investigational gene therapy, valoctocogene...
